Back to Results
First PageMeta Content
Biology / Perception / TRPV1 / Capsaicin / TRPV / Neuropathic pain / Discovery and development of TRPV1 antagonists / Hyperalgesia / Piquance / Pain / Ion channels / Mind


PHE377: A novel clinical-stage TRPV1 antagonist devoid of “class” side effects for the treatment of chronic pain syndromes Summary of the Opportunity PharmEste wishes to identify a partner for development and commerc
Add to Reading List

Document Date: 2012-11-09 04:33:07

Open Document

File Size: 63,27 KB

Share Result on Facebook

City

Milan / /

Company

PharmEste - PharmEste / AEs / CCI / /

/

Event

Product Issues / FDA Phase / Product Recall / /

Facility

Company’s pipeline / /

IndustryTerm

biopharmaceutical / food interaction / /

MedicalCondition

TRP-mediated diseases / target population experiencing Chronic / chronic pain / diabetic neuropathy / dysfunction / mechanical hyperalgesia / pain / injury / highly social impact disorder / neuropathic and inflammatory pain models / infection / chronic constriction injury / inflammation / chronic pain syndromes Summary / neurogenic inflammation / chronic pain syndromes / /

Person

Pharmeste / Claudio Semeraro / /

/

Position

CEO / /

Product

Paw / gabapentin / PHE377 / /

Technology

pharmacokinetics / pharmacodynamics / /

URL

http /

SocialTag